Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation.
暂无分享,去创建一个
[1] M. Georgescu,et al. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. , 2010, Neuro-oncology.
[2] J. Eschbacher,et al. NHERF-1: modulator of glioblastoma cell migration and invasion. , 2009, Neoplasia.
[3] F. Vazquez,et al. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN , 2009, Proceedings of the National Academy of Sciences.
[4] T. Franke,et al. PI3K/Akt: getting it right matters , 2008, Oncogene.
[5] M. Georgescu,et al. Roles of NHERF1/EBP50 in cancer. , 2008, Current molecular medicine.
[6] P. McCrea,et al. Cortical stabilization of β-catenin contributes to NHERF1/EBP50 tumor suppressor function , 2007, Oncogene.
[7] Yoko Takahashi,et al. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling , 2006, The EMBO journal.
[8] R. Kiss,et al. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Marion Müller-Borg,et al. Direct association of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals a link between the PAR/aPKC complex and phosphoinositide signaling , 2005, Development.
[10] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[11] L. Broemeling,et al. NHERF (Na+/H+ Exchanger Regulatory Factor) gene mutations in human breast cancer , 2004, Oncogene.
[12] Paola Pisani,et al. Genetic Pathways to Glioblastoma , 2004, Cancer Research.
[13] William R Sellers,et al. The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Hirohashi,et al. EBP50, a β‐catenin–associating protein, enhances Wnt signaling and is over‐expressed in hepatocellular carcinoma , 2003, Hepatology.
[15] C. Ross,et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[16] Tomohiko Maehama,et al. Crystal Structure of the PTEN Tumor Suppressor Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association , 1999, Cell.
[17] H. Hanafusa,et al. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Merlo,et al. Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.
[19] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[20] Dario R. Alessi,et al. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro , 1998, Current Biology.